BioNexus Gene Lab Corp. Files 8-K on Security Holder Rights

Ticker: BGLC · Form: 8-K · Filed: Apr 10, 2025 · CIK: 1737523

Bionexus Gene Lab CORP 8-K Filing Summary
FieldDetail
CompanyBionexus Gene Lab CORP (BGLC)
Form Type8-K
Filed DateApr 10, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, rights-modification, sec-filing

TL;DR

BioNexus Gene Lab Corp. just filed an 8-K about changes to security holder rights - check it out!

AI Summary

BioNexus Gene Lab Corp. filed an 8-K on April 10, 2025, reporting a material modification to the rights of its security holders as of April 7, 2025. The filing indicates a change in the company's corporate structure or governance that affects the rights associated with its securities.

Why It Matters

This filing signals a significant change in the company's structure or governance that could impact the rights and value of its outstanding securities.

Risk Assessment

Risk Level: medium — Material modifications to security holder rights can introduce uncertainty and potential risks for investors.

Key Numbers

Key Players & Entities

FAQ

What specific modification was made to the rights of security holders?

The filing states 'Material Modifications to Rights of Security Holders' as the item information, but the specific details of the modification are not provided in the excerpt.

When did the modification to security holder rights become effective?

The earliest event reported is dated April 7, 2025, which is the date as of which the modification is effective.

What is the company's principal executive office address?

The company's principal executive offices are located at Unit A-28-7, Tower A, Menara UOA Bangsar, No.5 Jln Bangsar Utama 1, 59000 Kuala Lumpur.

What is the company's state of incorporation?

BioNexus Gene Lab Corp. is incorporated in Wyoming.

What is the company's SIC code?

The company's Standard Industrial Classification (SIC) code is 8071, which corresponds to Medical Laboratories.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 10, 2025 regarding BioNexus Gene Lab Corp (BGLC).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing